<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478503</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-031</org_study_id>
    <nct_id>NCT01478503</nct_id>
  </id_info>
  <brief_title>To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Dose-escalating, Exploratory Study to Investigate the Pharmacokinetics, Safety and Tolerability of Multiple Doses of YM178 OCAS-M in Healthy Young Male and Female Subjects and Healthy Elderly Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aimed to compare age and gender differences for increasing doses of mirabegron when&#xD;
      given to healthy young and elderly males and healthy young and elderly females.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will receive a single dose of mirabegron OCAS-M or placebo on Day 2, followed by&#xD;
      multiple dosing (qd) for 10 days (Day 5-14).&#xD;
&#xD;
      Young subjects will be divided into 4 groups and elderly subjects into 2 groups. Dosage will&#xD;
      be different among groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of mirabegron assessed by plasma concentration</measure>
    <time_frame>Pre-dose until 72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG), clinical safety laboratory and adverse events</measure>
    <time_frame>Baseline until 72 hours after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron OCAS</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <other_name>YM178 OCAS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy young subjects aged 18-55 years (inclusive)&#xD;
&#xD;
          -  Healthy elderly subjects aged 65-80 years (inclusive)&#xD;
&#xD;
          -  Body weight between 60.0 and 100.0 kg (male) or between 50.0 and 90.0 kg (female), and&#xD;
             Body Mass Index between 18.0 and 30.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to β-adrenergic receptor agonists or any&#xD;
             components of the formulation used&#xD;
&#xD;
          -  Any of the liver function tests (i.e. ALT, AST and bilirubin) above the upper limit of&#xD;
             normal at repeated measures&#xD;
&#xD;
          -  Any clinically significant history of any other disease or disorder -&#xD;
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,&#xD;
             dermatological, psychiatric or metabolic as judged by the medical investigator.&#xD;
&#xD;
          -  Any clinically significant abnormality following the investigator's review of the&#xD;
             pre-study physical examination, electrocardiogram (ECG) and clinical laboratory tests&#xD;
&#xD;
          -  Subjects taking β blockers or β agonists&#xD;
&#xD;
          -  Use of any prescribed or Over-the-counter (OTC) drugs (including vitamins, natural and&#xD;
             herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the&#xD;
             Clinical Unit, except for occasional use of paracetamol (up to 3 g/day)&#xD;
&#xD;
          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the&#xD;
             3 months prior to admission to the Clinical Unit&#xD;
&#xD;
          -  Donation of blood or blood products within 3 months prior to admission to the Clinical&#xD;
             Unit&#xD;
&#xD;
          -  Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or&#xD;
             more than 21 units of alcohol per week within the 3 months prior to study&#xD;
&#xD;
          -  Participation in any clinical study within 3 months or participation in more than 3&#xD;
             clinical studies within 12 months, prior to the expected date of enrolment into the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kendle Nederland</name>
      <address>
        <city>Utrecht</city>
        <zip>358 CJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma Bio Research</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9470 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=651</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.</citation>
    <PMID>23063375</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Dose-Escalation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

